초대배양한 신장 근위세뇨관세포에서 estradiol-17β와 IGF-I 수용체 발현과의 상관관계

한호재,남성안,박권무,Han, Ho-jae,Nam, Seong-ahn,Park, Kwon-moo 대한수의학회 1997 大韓獸醫學會誌 Vol.37 No.2

The mechanisms of $estradiol-17{\beta}$ regulating growth of both normal and neoplastic cells are not clear until now. In studies using various estrogen-dependent breast cell lines, it is recently known that estrogen controls the cell growth by regulating the expression of growth factors and/or their receptors. In the present study, we investigated the effects of $estradiol-17{\beta}$on cell growth and IGF-I binding sites using primary cultured renal proximal tubule cells. We have obtained results as follows : $Estradiol-17{\beta}(10^{-9})$ has stimulatory effects in cell growth. Cotreatment of $estradiol-17{\beta}(10^{-9}M)$ and $IGF-I(5{\times}10^{-8}M)$ significantly increased the growth of primary rabbit renal proximal tubule cells compared to that of $estradiol-17{\beta}$ or IGF-I alone treated cells. In binding studies, we found that the binding of $^{125}IGF-I$ on cell membranes was incubation time- and temperature-dependent. Incubation at $37^{\circ}C$ results in higher binding of $^{125}IGF-I$ than that of $23^{\circ}C$ or $4^{\circ}C$. Maximum binding was observed at $37^{\circ}C$ between 30 and 60 minutes. The binding of $^{125}IGF-I$ to both control and $estradiol-17{\beta}-treated$ cells was inhibited by unlabelled $IGF-I(10^{-8}{\sim}10^{-12}M)$ in a concentration-dependent manner. However, EGF did not compete for $^{125}IGF-I$ binding at $10^{-8}{\sim}10^{-12}M$. IGF-I binding to the membranes from both control and $estradiol-17{\beta}-treated$ cells was also analyzed. We found that $estradiol-17{\beta}-treated$ cells exhibited higher binding activity for IGF-I. When $estradiol-17{\beta}$ or tamoxifen alone, or $estradiol-17{\beta}$ and tamoxifen cotreated cells were compared, the binding ratio of $^{125}I-IGF-I$ of $estradiol-17{\beta}-treated$ cell was significantly increased but was similar to control in both $estradiol-17{\beta}$ and tamoxifen cotreated cell. These results suggest that $estradiol-17{\beta}$ in part controls cell proliferation by regulating the expression of IGF-I receptors in primary rabbit renal proximal tubule cells.

한국인 폐경 여성에서 Drospirenone 2 mg과 17β-estradiol 1 mg 투여의 혈압, 체중, 지질의 영향

신유정 ( You Jung Shin ),이선주 ( Sun Joo Lee ),권수경 ( Su Kyeong Kwon ),유래미 ( Rae Mi Yu ),강혁재 ( Hyuk Jae Kang ),김성훈 ( Sung Hoon Kim ),채희동 ( Hee Dong Chae ),김정훈 ( Chung Hoon Kim ),강병문 ( Byung Moon Kang ) 대한폐경학회 2011 대한폐경학회지 Vol.17 No.2

연구목적: 현재 17β-estradiol/drospirenone 혼합제제는 폐경 여성의 호르몬 치료로 사용되고 있다. 하지만 아직 한국여성에서의 drospirenone 제제의 심혈관에 대한 영향 및 부작용에 대한 연구가 부족하며 논란이 있는 실정이다. 따라서 본 연구에서는 현재 이용되고 있는 17β-estradiol/drospirenone 혼합제제의 혈압 강하 및 지질수치 변화에 대한 효과를 24개월에 걸쳐 평가하고 약제에 대한 부작용에 대하여 살펴 보고자 한다. 연구재료 및 방법: 2007년 12월부터 2010년 10월까지 울산의대 서울아산병원 산부인과에 방문하여 폐경이 진단되고 drospirenone/17β-estradiol 혼합제제를 처음으로 처방받은 총 417명의 여성을 대상으로 후향적으로 의무 기록을 검토하였다. 혈압 측정을 시행한 125명의 환자를 이들의 혈압에 따라 그룹 1 (정상 혈압군, n = 76)과 그룹 2 (고혈압전기 또는 고혈압 1기 환자, n = 49)로 나누어 호르몬 복용 이전에 혈압과 체중, 혈액검사를 시행하고 복용 시작 1, 2, 3, 6, 9, 12, 18, 24개월 후에 측정한 값들과의 비교를 시행하였다. 그리고 지질 수치는 복용 전과 복용 시작 6, 12, 24개월 후의 총 콜레스테롤, 저밀도 지단백, 고밀도 지단백 그리고 중성 지방 수치를 비교하였다. 또한 drospirenone/17β-estradiol 혼합제제의 안정성을 평가하기 위해 중단 및 약제 변경의 사유와 투약 후 나타난 부작용에 대해 평가하였다. 통계는 기준선의 특징에 대해서는 SPSS version 12.0 (SPSS Inc., Chicago, IL, USA)를 사용하고 투여 전후 혈압, 체중, 지질 수치 변화에 대해서는 Statistical Analysis System (SAS) version 9.1 (SAS Institute Inc., Cary, NC, USA)을 사용하였다. 결과: 최초 진단 후 처방 당시 환자 평균 연령은 52.4 ± 3.9 세였으며, 복용 일의 중앙값은 279 일이었다. 폐경여성에서 drospirenone/17β-estradiol 혼합제제의 투여 후, 그룹 1과 2에서 혈압이 통계적으로 유의하게 감소하였다. 하지만 체중의 변화는 통계적으로 유의한 감소는 없었으며, 지질 수치의 변화는 측정한 값 중 중성지방만이 의미있는 감소가 있었으나, 각 측정시기만을 고려했을 때는 복용 후 18개월 후 저밀도 지단백 그리고 중성 지방 수치의 의미있는 감소가 있었다. Drospirenone/17β-estradiol 혼합제제 복용 중단 또는 약물 변경한 주요 이유로는 점상 질출혈 (28%), 부작용에 대한 두려움 (27%), 증상에 효과가 없었던 경우 (26%)의 순으로 나타났다. 결론: Drospirenone/17β-estradiol 혼합제제 복용은 폐경 여성의 수축기와 이완기 혈압을 의미있게 감소시켰으며 체중 감소는 있었으나 통계적 유의성을 보이지는 않았다. 그리고 지질 수치 중 중성지방이 유의하게 감소하였으며 심각한 부작용은 관찰되지 않았다. Objectives: The objective of the present study was to determine the effects of the widely used combination hormone therapy, drospirenone and 17β-estradiol on the blood pressure, body weight, lipid profiles, and major side effects in postmenopausal Korean women. Methods: Four hundred seventeen menopausal patients who were being treated with drospirenone/17β-estradiol at the Asan Medical Center between December 2007 and October 2010 underwent a retrospective chart review. One hundred twenty-five patients were divided into 2 groups based on blood pressure, as follows: group 1 (normal blood pressure, n = 76); and group 2 (stage 1 hypertension and pre-hypertension, n = 49). The systolic and diastolic blood pressure and the body weight were checked before the treatment, and 1, 2, 3, 6, 9, 12, 18 and 24 months after taking the medication. Results: The median days of administration were 279. The combination of drospirenone and 17β-estradiol had a blood pressure-lowering effect in groups 1 and 2. However, the body weight did not show a statistically significant change. Only the level of triglycerides decreased with time and the change was statistically significant. The low density lipoprotein (LDL)-cholesterol and triglycerides levels had a statistically significant decrease 18 months after the medication. The most common reasons for discontinuouing medication were vaginal spotting (28%), fear of side effects (27%), and ineffectiveness (26%). Conclusion: The combination of drospirenone/17β-estradiol caused a decrease in systolic and diastolic blood pressure and the body weight showed no statistically significant decrease. Furthermore, triglycerides showed statistically significant decrease and there were no severe side effects of the medication reported. (J Korean Soc Menopause 2011;17:102-109)

치주인대세포 배양에서 estrogen이 growth hormone receptor의 발현유도에 미치는 영향

홍성규,전영미,김정기 대한치과교정학회 2000 대한치과교정학회지 Vol.30 No.4

본 실험은 사람의 치주인대세포에서 에스트로겐과 growth hormone(GH)이 상호 어떠한 작용을 하는지를 규명하는 것이 목적이다. 교정치료를 받고자 내원한 환자중에서 건강한 20대 여자환자들의 상하악 제1소구치를 발거하여, 치근의 중간 1/3부위에서 긁어모은 치주인대 조직을 배양하여 치주인대세포를 얻었다. 사람의 치주인대세포의 분열증식에 대한 17β-estradiol과 hGH의 효과를 평가하고, 치주인대세포에 17β-estradiol을 전처리한 후 치주인대세포의 분열증식에 미치는 hGH의 효과 변화를 평가하였으며, 치주인대세포에 17β-estradiol을 전처리 하였을 경우 치주인대세포에서 hGH receptor의 발현 양상의 변화를 평가하여 다음과 같은 결론을 얻었다. 1.17β-estradiol이나 human growth hormone의 단독처리는 사람의 치주인대세포의 분열증식에 큰 영향을 주지 않는다. 2.17β-estradiol 10-12M로 전처리한 후 hGH를 투여한 경우 hGH의 농도에 관계없이 사람의 치주인대세포의 분열증식을 증가시킨다. 3.사람의 치주인대세포에는 hGH receptor가 없으나, 17β-estradiol 10-12M로 6시간 이상 처리하면 hGH receptor가 발현된다. 4.hGH이 사람의 치주인대세포의 분열증식에 미치는 효과는 hGH receptor의 발현과 관련이 있으며, 17β-estradiol의 전처리가 치주인대세포에서의 hGH receptor의 발현에 기여함으로써 hGH이 치주인대세포에 작용할 수 있도록 해준다. The present studies were performed to investigate the interaction of 17β -estradiol and human growth hormone(hGH) on the proliferation of human periodontal ligament(hPDL) cell. The independent effects of 17β-estradiol and hGH on hPDL cell proliferation were investigated and the effects of hGH on hPDL cell proliferation after 17β-estradiol pre-treatment were also investigated. Lastly, the change of hGH receptor expression in hPDL cell after 17β-estradiol pre-treatment were investigated. The obtained results were as follows; 1.The treatment of 17β-estradiol or hGH had no significant effects on hPDL cell proliferation. 2.After pre-treatment of 17β-estradiol, hGH stimulated the proliferation of the hPDL cell, regardless of hHG concentration. 3.Although there was not hGH receptor in the hPDL cell, hGH receptors were expressed in hPDL cell after more than 6 hours pre-treatment of 17β-estradiol. 4.The effect of hGH on hPDL cell proliferation was related to the hGH receptor expression. 17β -estradiol pre-treatment contributed to the hGH effects on the hPDL cell by stimulating hGHR expression.

17β-estradiol의 고혈압 유도반응 억제와 인체적용 전기자극의 17β-estradiol 활성 증가

김중환 ( Jung-hwan Kim ) 대한물리치료학회 2009 대한물리치료학회지 Vol.21 No.2

Purpose: 17β-estradiol is the most active endogenous estrogen, which is related to favorable changes in the plasma lipid profile, to relaxation of the coronary vessels, and to a decrease in platelet aggregation and vascular smooth muscle cell migration. However, although the beneficial effect of estrogens on plasma lipoproteins (ie, lowering low-density lipoprotein and increasing high-density lipoprotein cholesterol) contributes to cardiovascular protection, it does not fully account for the protective effect, particularly in the application of physical therapy, including low frequency electrical stimulation. Methods: The aim of this study was to demonstrate the inhibition of stressors, such as endothelin-1 (ET-1), serotonin (5-hydroxytryptamine, 5-HT), prostaglandin F2α (PGF2α), and a protein kinase C (PKC) activator 12-deoxyphorbol 13- isobutyrate (DPB), induced isometric tension by 17β-estradiol in vascular smooth muscle strips, respectively. In addition, the effects of low frequency electrical stimulation at the meridian points (CV-3, -4, Ki-12, SP-6, LR-3, BL-25, -28, -32, -52) on the indirect antihypertensive effect were examined by monitoring the changes in the serum 17β-estradiol concentration in healthy volunteers. Results: Isometric tension analysis showed that the responses of inhibited tension by 17β-estradiol were similar to the same stressors in rat aortic smooth muscle strips. Furthermore, although the continued amplitude modulation (AM) type of electrical stimulation was not increased significantly by electrical stimulation, the current of the frequency modulation (FM) type of low frequency electrical stimulation increased the serum 17β-estradiol concentration in normal volunteers. Conclusion: These results, in part, suggest that 17β-estradiol has the capacity to supress stressor-induced muscle tension, and electrical stimulation, particularly current of the FM type, has a modulatory effect on the sex steroid hormones, particularly 17β-estradiol, in healthy volunteers.

저지방식이를 섭취한 난소절제 암컷 쥐에서 지질대사에 대한 fenofibrate과 17β-estradiol의 영향

정선효 한국응용과학기술학회 2019 한국응용과학기술학회지 Vol.36 No.4

It was studied whether fenofibrate alone or combinational treatments of fenofibrate and 17β-estradiol regulates serum lipid levels, and whether the effects of fenofibrate on serum lipid metabolism are affected by co-administration of 17β-estradiol in low-fat diet-fed ovariectomized female mice. Compared with low-fat diet-fed controls, mice treated with fenofibrate alone and mice treated with fenofibrate and 17β-estradiol didn’t decrease body weight at 8 weeks. Fenofibrate alone or combinational treatments of fenofibrate and 17β-estradiol did not regulate serum levels of total cholesterol and HDL-cholesterol. Fenofibrate decreased plasma levels of LDL-cholesterol and triglycerides compared with controls. The combinational treatments of fenofibrate and 17β-estradiol showed more beneficial effects on triglycerides than fenofibrate alone. Therefore, the present study found that serum triglycerides reduced by fenofibtae treatment alone could be more improved by combinational treatments of fenofibrate and 17β-estradiol in low-fat diet-fed ovariectomized female mice. 본 연구는 저지방식이를 섭취한 난소절제 암컷 쥐에서 피노피브레이트(fenofibrate) 단독처리 및피노피브레이트와 17베타-에스트라다이올(17β-estradiol)과의 동시처리가 혈청 속 지질대사를 조절하는지를 조사하였고, 피노피브레이트와 17베타-에스트라다이올의 동시처리에 의해 혈청 속 지질대사에 대한 피노 피브레이트 단독처리의 효과가 어떻게 조절되는지를 연구하였다. 저지방식이만을 섭취한 대조군에 비해 피노 피브레이트가 단독처리된 쥐와 피노피브레이트와 17베타-에스트라다이올이 동시처리된 쥐의 8주째 몸무게는 감소되지 않았다. 피노피브레이트 단독처리와 피노피브레이트와 17베타-에스트라다이올 동시처리는 혈청 속 총 콜레스테롤과 HDL-콜레스테롤을 감소시키지 않았다. 피노피브레이트는 대조군에 비해 혈청 속 LDL-콜레스테롤과 중성지방을 감소시켰다. 피노피브레이트 단독처리에 비해 피노피브레이트와 17베타-에 스트라다이올 동시처리는 혈청 속 중성지방에 대해 유익한 변화를 나타내었다. 따라서 본 연구는 저지방식이를 섭취한 난소절제 암컷 쥐에서 fenofibtae 단독처리에 의해 감소된 혈청 속 중성지방은 피노피브레이트와 17베타-에스트라다이올의 동시처리에 의해 개선될 수 있음을 발견하였다.

제주마(濟州馬)의 혈청 progesterone 및 estradiol-17β의 임신진단(姙娠診斷) 이용에 관한 연구

최한호(Han Ho Cho),강민수(Min Soo Kang) 제주학회 2001 濟州島硏究 Vol.20 No.-

암말 238두를 대상으로 번식과정에 있어서 혈장 progesterone과 estradiol-17β의 수준변화를 분석하여 초음파진단 결과와 상관관계를 구명함으로써 개별농가에서 자연교배로 자체번식에 의해 교잡종의 번식을 행하고 있는 현 제주마 번식관리 체계하에서 실용적인 측면에서 효율적인 임신진단방향을 모색코자 실시한 시험결과를 요약하면 다음과 같다. 1. 임신마에 있어서 혈청 progesterone 수준이 13.43ng/㎖인 반면 비임신마에서는 3.83 ng/㎖였다. estradiol-17β 수준은 임신마에서 1.020.90pg/㎖, 비임신마는 12.08pg/㎖였다. 따라서 임신마와 비임신마간에는 고도의 유의차가 인정되었다. 2. 초음파진단 임신마는 progesterone 수준이 4.7ng/㎖ 이상에서 89.5%, 4.6ng/㎖ 이하가 10.5%인 반면 비임신마에서는 4.6ng/㎖ 이하가 63.5%, 4.7ng/㎖ 이상 36.5%였다. EStradiol-17β 수준은 임신마의 경우 160.9pg/㎖ 이상의 높은 농도를 나타 낸 반면 비임신마의 경우에는 90.9%가 l06pg/㎖ 이하의 수치를 보였다. 3. 번식계절을 중심으로 4월~9월까지는 임신초기 말이 많은 기간에는 progesterone을 측정하여 10~3월까지는 임신말기 말이 많으므로 임신후기에 분비량이 많아지는 estradiol-17β를 측정하므로서 임신진단의 정확도가 높아질 것으로 사료된다. 4. 제주마혈통등록친자 감별 체계의 미확립으로 인해 교배 및 임신시기 파악이 곤란한 실정으로써 조방적 사육과 순치 불량 등으로 인하여 초음파 기기에 의한 직장검사가 어려운 경우가 많다. 혈중 progeoterone 수준이 16.9ng/㎖ 이상에서는 100%의 임신 진단율을 보였다. Estradlil-17β 수준은 160.9pg/㎖ 이상인 말에서 100%가 임신된 것으로 확인되었다. 따라서 혈중 성 steroid 호르몬 측정에 의한 임신진단 방법은 초음파 진단과 병행 실시한다면 검사시간과 인력 그리고 마필자체의 부상위험성 등을 줄일 수 있는 예비검사(screening test)로서 충분한 활용가치가 있을 것으로 사료된다. Through comparing the concentration change of plasma progesterone and estradiol-17β with the results of clinic ultrasonic diagnosis during the reproduction period of 238 mares in Cheju-island, where individual farmers breed their crossbreed by natural mating and their own breeding, this study has been carried out to find efficient methods of pregnancy diagnosis on mare in practical aspects, summary of this study is as follows; 1. Pregnant mares show average 13.43ng/㎖ of progesterone level and non-pregnant mares, 3.83ng/㎖ In estradiol-17β concentration, pregnant mares show average 1,020.90pg/㎖ and non-pregnant mares, 12.08pg/㎖. Therefore the results between pregnant and non-pregnant mares are highly correlative. 2. In clinic ultrasonic diagnosis, 89.5% pregnant mares show over 4.7ng/㎖ of progesterone level, 10.5% pregnant mares, less 4.6ng/㎖ On the other hand, 63.5% non-pregnant mares show less 4.6ng/㎖ of progesterone level, 36.5% non-pregnant mares, over 4.7ng/㎖. In addition, pregnant mares show over 160.9pg/㎖ of estradiol-17β level and 90.9% non-pregnant mares, less 10.6pg/㎖. 3. During breeding seasons, normally April-September, the concentration of progesterone can show early pregnancy status on Cheju mares. And on the period of October-next March, the test of estradiol-17β, which is in high level at the latter pregnancy period, can increase the accuracy of pregnancy diagnosis on Cheju mares in taller pregnancy. 4. The insufficient registry of blood-line and parentage test system of Cheju mares makes it difficult find the proper mating time and pregnant seasons. And the ultrasonic test of rectal intestine on Cheju mares is mostly difficult due to grazing system on the pasture and incomplete taming. In this study, Cheju mares with over 16.9ng/㎖ of progesterone level or 160.9pg/㎖ of estradiol-17β level were confirmed 100% pregnant. Therefore, the pregnancy test method by the level of sex steroid hormone in mare plasma with the proper ultrasonic test shall be sufficiently an efficient screening test to save testing time and manpower, lessen the risk of injury on the mares themselves.

17β-estradiol Prevents the Expression of CEBPα-mediated Adipocyte Marker Genes in Female Ovariectomized C57BL/6 Mice

Michung Yoon,Sunhyo Jeong 대한의생명과학회 2008 Biomedical Science Letters Vol.14 No.3

Adipogenesis is a complex sequence of events that culminates in the differentiation of fibroblast-like preadipocytes into specialized lipid-filled adipocytes and also involves a cascade of expression of many transcription factors such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding proteins (C/EBPs). PPARγ and C/EBPs transcriptionally transactivate adipocyte specific genes, including fatty acid transport protein (FAT/CD36) and leptin. To determine whether 17β-estradiol modulates C/EBPα actions on adipogenesis in high fat diet-fed female ovariectomized (OVX) C57BL/6 mice, mice were treated with 17β-estradiol for 7 days and the effects of 17β-estradiol on adipose tissue mass and expression of adipocyte specific gene as well as C/EBPα were measured. Compared to vehicle-treated OVX control mice, OVX mice treated with 17β-estradiol for 7 days had lower adipose tissue weights that were similar to weights in high fat diet-fed sham-operated (Sham) mice. OVX mice showed the increased expression of C/EBPα mRNA compared with Sham mice. However, 17β-estradiol treatment in OVX mice inhibited OVX induced-C/EBPα activation, indicating that 17β-estradiol may act as an inhibitor of C/EBPα action. Moreover, 17β-estradiol decreased mRNA levels of adipocyte marker genes, such as lipoprotein lipase, FAT/CD36 and leptin, to levels in Sham mice. These results suggest that down-regulation of adipogenesis by 17β-estradiol may be due to reduced adipose C/EBPα activities in female OVX C57BL/6 mice.

Endothelin - 1 에 의한 돼지 관상동맥 수축에 미치는 17β - Estradiol 의 효과

정호경(Ho Gyeong Jeong),강병선(Byeong Sun Kang),김민구(Min Gu Kim),박병건(Byeong Gun Park),황진용(Jin Yong Hwang),서봉관(Byeong Sun Kang) 대한내과학회 1997 대한내과학회지 Vol.52 No.2

Objectives: It is widely accepted that estrogen has favorable effects on cardiovascular diseases, especially in the postmenopausal women. Endothelin- 1(ET-I), released from the vascular endothelium, is a 21-amino acid peptide with strong vasoconstrictor activity. However, the effect of estrogen on the vasoconstriction to ET-1 has not been extensively studied. Methods: To investigate the effect of estrogen (175β-estradiol) on the vascular contraction to ET-1, porcine coronary artery(PCA) rings were suspended in organ chambers(37℃, 95% O2/5% CO2) for measurement of isometric tension change. Endothelium was removed mechanically if necessary. In acute experiments, vascular rings were preincubated for 15minutes with 3different concentrations of 170β-estradiol(10(-6), 10(-5), 10(-4)M) and concentration-contraction curves to cumulative doses of ET-1 were constructed. In the experiments after a longer exposure to 17β-estradiol, the vessels with endothelium were exposed in the 5% CO2 incubator to 3different concentrations of 17β-estradiol(10(-9), 10(-8), 10(-7) M) for 44-50 hours, and then concentrationcontraction curves to ET-1 were obtained. Results: Incubation for 15minutes with 170β-estradiol(10 -4)M) inhibited ET-1-induced contraction in the vessels with endothelium(area under the curve and maximal contraction, p<0.05 compared with control). This effect persisted regardless of the sex and the presence or absence of the endotheliurn. Incubation of the vessels far a longer time with 170β-estradiol(44-50 hours) resulted in the inhibition of maximal contraction to ET-1(p<0.05) by a lower concentration of 175β-estradiol(10(-7)M) than in acute experiments in male PCA rings, but an enhanced contraction to ET-1(area under the curve; p<0.05) by 10M of 175β-estradiol was observed in female PCA rings. Conclusion: Short-time incubation with 17Pβ-estradiol has an inhibitory effect on the contraction to ET-1 in PCA rings. This effect is independent of the presence of the endothelium and the sex of the pigs. A longer incubation with 17β-estradiol results in a similar inhibitory effect on male(but not female) PCA rings, suggesting that a sex-related difference may exist concerning the effect of 17β-estradiol on ET-1-induced contraction.

17Beta-estradiol Stimulates Glucose Uptake Through Estrogen Receptor and AMP-activated Protein Kinase Activation in C2C12 Myotubes

이기호,조경진,김주영,백행운,이성규 대한비만학회 2016 The Korean journal of obesity Vol.25 No.4

Background: Previous studies have shown that 17beta-estradiol activates AMP-activated protein kinase (AMPK) in rodent muscle and C2C12 myotubes and that acute 17beta-estradiol treatment rapidly increases AMPK phosphorylation possibly through non-genomic effects but does not stimulate glucose uptake. Here, we investigated whether 24-hour 17beta-estradiol treatment stimulated glucose uptake and regulated the expression of genes associated with glucose and energy metabolism through the genomic effects of estrogen receptor (ER) in C2C12 myotubes. Methods: C2C12 myotubes were treated with 17beta-estradiol for 24 hours, and activation of AMPK, uptake of glucose, and expression of genes encoding peroxisome proliferator-activated receptor γ coactivator 1α, carnitine palmitoyltransferase 1β, uncoupling protein 2, and glucose transporter 4 were examined. Furthermore, we investigated whether AMPK inhibitor (compound C) or estrogen receptor antagonist (ICI182.780) treatment reversed 17beta-estradiol-induced changes. Results: We found that 24-hour treatment of C2C12 myotubes with 17beta-estradiol stimulated AMPK activation and glucose uptake and regulated the expression of genes associated with glucose and energy metabolism. Treatment of C2C12 myotubes with the estrogen receptor antagonist (ICI182.780) reversed 17beta-estradiol-induced AMPK activation, glucose uptake, and changes in the expression of target genes. Furthermore, treatment with the AMPK inhibitor (compound C) reversed 17beta-estradiol-induced glucose uptake and changes in the expression of target genes. Conclusion: Our results suggest that 17beta-estradiol stimulates AMPK activation and glucose uptake and regulates the expression of genes associated with glucose and energy metabolism in C2C12 myotubes through the genomic effects of ER.

P184 : Retrospective comparison of efficacy and safety of 17 α-estradiol solution on male androgenetic alopecia treated with finasteride

( Hyung Il Kwon ),( Su Jin Oh ),( Seong Hun Moon ),( Jeong Eun Kim ),( Joo Yeon Ko ),( Young Suck Ro ) 대한피부과학회 2014 대한피부과학회 학술발표대회집 Vol.66 No.2

Background: Androgenetic alopecia (AGA) is the most common cause of hair loss in both sexes in adulthood. 17α -estradiol solution acts to suppress hair loss and promote hair growth by inhibiting 5α-reductase and 17β-dehydrogenase which lead to increased conversion of testosterone to estradiol. But it has been used mainly for female AGA. Objectives: To examine the efficacy and safety of 17α -estradiol solution in Korean male patients with AGA. Methods: A retrospective study of 125 patients with AGA who had been taking finasteride with or without using 17α -estradiol solution was performed. We analyzed the efficacy and safety of 17α-estradiol solution. The efficacy was evaluated by investigator global assessment (IGA) score via clinical photographs, phototrichogram analysis and the safety was reported by medical records. Results: Clinical photographs showed improvement in both groups, but the increase of IGA score was not statistically significant between them (p=0.273). Hair counts and diameter after treatment increased in both groups and the changes on hair diamter showed better response in the experimental group with statistical significance (p<0.001). 17 α-estradiol solution showed some mild local reactions such as erythema and itching, which were tolerable. No systemic reaction was observed. Conclusion: This study showed that 17α-estradiol solution is effective and safe when combined with finasteride in the treatment of male AGA.